Research Projects
|
Title: |
Bupropion for the Treatment of
Methamphetamine Dependence: Phase
2/Double Blind |
|
Principal Investigator: |
Daniel Dickerson, D.O., MPH |
|
Research Coordinator: |
Winnie Tsai |
|
Funded by: |
National Institute on Drug Abuse |
|
Grant Number: |
R01 DA019063-01 |
|
Total Project Period: |
2009-2010 |
Project Description:
Methamphetamine has become a major drug of
abuse in this country for nearly a decade.
As a result, the development of effective
treatments for methamphetamine dependence
has become a pressing concern for the
national and global drug abuse treatment
community. This project tests whether the
drug, Bupropion, taken orally, is useful and
safe for treating methamphetamine addiction.
Two hundred ten (210) men and women at 12
research sites across the United States will
participate in this study.
|
Title: |
Cognitive Behavior Therapy for the
Republic of South Africa (CBT for
RSA) |
|
Principal Investigator: |
|
|
Site
Principal Investigator: |
Frank J.
Vocci, Ph.D. |
|
Research Coordinator: |
|
|
Funded by: |
National Institute on Drug Abuse |
|
Grant Number: |
R01 DA019063-01 |
|
Total Project Period: |
2005-2010 |
Project Description:
This project adapts and evaluates CBT for
use with RSA clinicians. The goal of this
project is to assess the effectiveness of
three (3) training approaches on Republic of
South Africa (RSA) clinicians’ ability to
adhere to the core elements of a research
based model for individual Cognitive
Behavioral Therapy that is adapted for use
in RSA. In this regard, this project will
examine three methods of training 150 RSA
clinicians at 30 treatment centers in a
12-session CBT intervention adapted from the
Carroll CBT model. These methods include: 1)
An in-vivo (IV) CBT training and
supervision program in which clinicians
receive training and supervision with CBT
from a South African Professional who will
be trained in the United States (US) by an
Expert Trainer; 2) A distance learning only
(DLO) training and supervision approach, in
which RSA clinicians will receive training
and supervision via a teleconferenced and
interactive broadcast originating in South
Africa with a South African Professional who
will be trained in the US by an Expert
Trainer; and 3) A self instructional manual
only approach (MO). We will measure the
knowledge and skills of individual RSA
therapists to deliver individual CBT for
cocaine abuse. Further, we will calculate
the cost of delivering each of the training
models in order to allow an impact analysis
of the training efforts to consider the real
world limitations associated with training
costs. It is expected that these methods for
the training of RSA community-based
treatment organizations will provide
empirical data on how to best facilitate
their adoption of evidence-based CBT
techniques for cocaine treatment in RSA and
the United States (US).
|
Title: |
Eli Lilly Pharma. Maintenance of
Response After Open-Label Treatment
with Atomoxetine Hydrochloride in
Adult Outpatients with Attention
Deficit/Hyperactivity Disorder
(ADHD): A Placebo-Controlled,
Randomized Withdrawal Study
|
|
Principal Investigator: |
|
|
Site
Principal Investigator: |
Daniel L. Dickerson, D.O. |
|
Research Coordinator: |
Aya
Fukuma |
|
Funded by: |
Eli
Lilly |
|
Total Project Period: |
2008-2010 |
Project Description:
Attention Deficit Hyperactivity Disorder
(ADHD) has been primarily classified as a
childhood disorder. However recently, adult
diagnoses are on the rise and multiple
treatments are available to those who seek
medical or psychiatric evaluation.
Atomoxetine, also known as Strattera has
been FDA approved to reduce the symptoms of
ADHD. This clinical trial will further test
the efficacy of this medication. Up to
1,925 participants will be enrolled in this
study worldwide.
|
Title: |
Faith-Based Addiction Training
Initiative |
|
Principal Investigator: |
|
|
Research Coordinator: |
Winnie
Tsai |
|
Funded by: |
Center of Substance Abuse Treatment
(CSAT) |
|
Total Project Period: |
2008-2013 |
Project Description:
Friends Research Institute via subcontract
with UCLA ISAP/Pacific Southwest Addiction
Technology Training Center is working with
faith-based organizations to: Develop an
infrastructure to assess the needs of the
region and promote technology transfer of
proven treatment services; Enhance knowledge
and expertise in addiction treatment and
recovery services by disseminating clinical
and research information; Upgrade the
standards of professional practice for
addiction workers to increase the number,
quality, and cultural competence
of substance abuse treatment professionals;
Develop scientifically-based substance use
disorders curricula and encourage academic
institutions to train and educate
pre-service students and practitioners.
|
Title: |
Titan Pharma. A Multi-Center Study of
Probuphine in Patients with Opioid
Dependence: A Randomized Placebo and
Active-Controlled Study.
|
|
Principal Investigator: |
Daniel L. Dickerson, D.O. |
|
Research Coordinator: |
Aya
Fukuma |
|
Funded by: |
Titan Pharmaceuticals, Inc. |
|
Total Project Period: |
2010-2012 |
Project Description:
The use of buprenorphine (BPN) for the
treatment of opioid dependence is now
well-established and is gaining increased
acceptance as a safe and useful office-based
treatment for opioid dependence. Probuphine,
an implantable formulation of buprenorphine
hydrochloride (HCl) has been shown to be
safe and well tolerated for Opioid addiction
in previous trials. This clinical trial will
further test the safety and efficacy of this
medication. Up to 250 participants will be
enrolled in this study.
Source: PRO-806 Clinical study protocol,
2009.
|
